Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 14/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | ATR | Q13535 | 1/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3512161 | 0.83 | BRD4 (0.49) | GLAMAPTBRD4FYNPIK3CA | |
| SCHEMBL13595838 | 0.81 | PIK3CA (0.67) | MAPTBRD4FYNPIK3CAATR | |
| SCHEMBL27782952 | 0.81 | BRD4 (0.54) | BRD4FYNPIK3CAATRPIK3CD | |
| SCHEMBL3514270 | 0.80 | BRD4 (0.62) | MAPTBRD4FYNPIK3CAATR | |
| SCHEMBL532033 | 0.80 | BRD4 (0.62) | MAPTBRD4FYNPIK3CAATR | |
| SCHEMBL4056538 | 0.80 | PIK3CA (0.67) | MAPTBRD4FYNPIK3CAATR | |
| SCHEMBL3511742 | 0.78 | BRD4 (0.60) | MAPTBRD4FYNPIK3CAATR | |
| SCHEMBL4060836 | 0.77 | FYN (0.60) | BRD4FYNPIK3CAATRPIK3CD | |
| SCHEMBL3512158 | 0.76 | BRD4 (0.49) | BRD4FYNPIK3CAATRPIK3CD | |
| SCHEMBL4054305 | 0.76 | PIK3CA (0.61) | MAPTBRD4FYNPIK3CAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| EP-2155753-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138834-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | GLA 3781/4885MAPT 4503/4885BRD4 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.